Sign inJoin waitlistJoin the waitlist

Edwin Posadas

Medical Director, Urologic Oncology Program · Cedars-Sinai Medical Center

Credentials: · · · ·

History

Urologic Oncology Program · Cedars-Sinai Medical Center
Present

Medical Oncology
2001–2003
National Cancer Institute
1998–2001
University of Michigan Medical School
1994–1998

Research

Large extracellular vesicles carry most of the tumour DNA circulating in prostate cancer patient plasma
Journal of Extracellular Vesicles · 2018 · 319 citations
Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma
Review · Hepatology · 2021 · 278 citations
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity
Journal of Clinical Oncology · 2008 · 266 citations

Stephen Freedland
25 papers
Robert Figlin
22 papers
JC
Jie-Fu Chen
16 papers
Jun Gong
15 papers · 2 as a fellow
HS
Howard Sandler
13 papers
YL
Yi-Tsung Lu
11 papers · 9 as a resident
Vatche Agopian
9 papers
Walter Stadler
9 papers
Beatrice Knudsen
8 papers
Phuoc Tran
8 papers
Felix Feng
7 papers
Jake Lichterman
7 papers

Grants

A Translational Study of a Synthetic Lethality Interaction of CD105 and Androgen Receptor Signaling Axis for Castration-Resistant Prostate Cancer Patients
National Cancer Institute · R01
PI · $2.9M · Cedars-Sinai Medical Center
2024–2029
Determinants of Liver Metastasis
National Cancer Institute · P01
Project lead · $1.3M · Cedars-Sinai Medical Center
2020–2025
A Blood Test to Identify Prostate Cancer Patients at Risk for Visceral Metastasis
National Cancer Institute · R01
Contact PI · $3M · Cedars-Sinai Medical Center
2017–2024
Thermoresponsive NanoVelcro CTC Purification System for Prostate Cancer Profiling
National Cancer Institute · U01
PI · $2.4M · University of California Los Angeles
2015–2021

Clinical trials

A Platform Study of Epigenetic Therapy Before Prostatectomy in Men With Prostate Cancer
Principal investigator · Recruiting · Early phase 1
Edwin Posadas, MD
2026–2029
Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
Principal investigator · Recruiting · Phase 2
Edwin Posadas, MD
2023–2027
A Study of Tazemetostat (Tazverik) Before Prostatectomy in Men With Prostate Cancer
Principal investigator · Withdrawn · Early phase 1
Edwin Posadas, MD
2023–2025
A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery
Principal investigator · Active not recruiting · Phase 2
RTOG Foundation, Inc.
2019–2029